论文部分内容阅读
目的评价联苯双酯滴丸对肝纤维化指标,透明质酸(HA),层粘连蛋白(LN),Ⅳ型胶原(Ⅳ-C),Ⅲ型前胶原(PCⅢ)水平与病理组织变化的影响。方法178例病毒性肝炎(乙型),慢性(中度)患者随机分成治疗组和对照组,用放射免疫法测定治疗组与对照组患者治疗前、后的血清HA、LN、Ⅳ-C、PCⅢ水平;肝活检取肝组织检查,观察两组患者治疗前、后炎症和纤维化程度变化。结果治疗组在治疗前、后血清HA、LN、Ⅳ-C、PCⅢ水平变化有显著性差异(P<0.05),病理组织结果显示炎症程度有显著改善,而纤维化程度无显著变化。对照组在治疗前、后肝纤维化指标和病理组织无显著变化。结论联苯双酯滴丸治疗病毒性肝炎(乙型),慢性(中度)患者可显著改善肝纤维化四项指标,而对病理组织中纤维化程度无显著改善。
Objective To evaluate the effects of bifendate on the changes of liver fibrosis indexes, the levels of hyaluronic acid (HA), laminin (LN), type Ⅳ collagen (Ⅳ-C), type Ⅲ procollagen influences. Methods A total of 178 patients with viral hepatitis (type B) and chronic (moderate) were randomly divided into treatment group and control group. The levels of serum HA, LN, Ⅳ-C and IL-6 in patients in treatment group and control group before and after treatment were determined by radioimmunoassay PCⅢ level; liver biopsy liver tissue was taken to observe the two groups of patients before and after treatment, inflammation and fibrosis changes. Results The levels of serum HA, LN, Ⅳ-C and PCⅢ in the treatment group before and after treatment were significantly different (P <0.05). The pathological results showed that the degree of inflammation was significantly improved, while the degree of fibrosis was not significantly changed. The control group before and after treatment, liver fibrosis indicators and pathological changes were not significant. Conclusions Biproxil drops treatment of viral hepatitis (B), chronic (moderate) patients can significantly improve the four indicators of liver fibrosis, while the pathological changes in the degree of fibrosis was not significantly improved.